Company: CERO
Filing Date: 2025-10-23
Form Type: 424B3
Source: 0001213900-25-101651
Chunk: 14

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-10-23
Form: 424B3
Chunk 14
---
 Certificate of Designations was filed pursuant to the Securities Purchase Agreement, dated October 14,
2025, with certain accredited investors named therein (the “Securities Purchase Agreement”), as previously reported by the
Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on October 14, 2025 (the “Prior Form
8-K”). The Certificate of Designations became effective on October 14, 2025.

The descriptions of the Series E Preferred Stock
and the Certificate of Designations as previously reported in the Prior Form 8-K are incorporated by reference herein. Such descriptions
do not purport to be complete and are qualified in their entirety by reference to the Certificate of Designations, which is filed as Exhibit
3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 8.01. Other Events.

On October 16, 2025, pursuant to the Securities Purchase
Agreement, as amended, the Company and certain accredited investors named therein, mutually agreed to effect, and effected, the Initial
Closing (as defined in the Securities Purchase Agreement), with respect to 3,816 shares of Series E Preferred Stock for gross proceeds
of approximately $2.25 million. The aggregate amount to be funded pursuant to the Securities Purchase Agreement remains $7 million, of
which $2.25 million was funded at the Initial Closing and $4.75 million remains to be funded at the additional closings. The rights, preferences
and privileges of the Series E Preferred Stock are set forth in the Certificate of Designations. The offering and sale of the shares of
Series E Preferred Stock were issued and, upon conversion of the Series E Preferred Stock, the shares of Common Stock underlying the Series
E Preferred Stock will be issued, in each case, without registration under the Securities Act, in reliance on the exemptions provided
by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) as a transaction not involving a public
offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under
applicable state laws.

The description of the terms and conditions of
the Securities Purchase Agreement does not purport to be complete and each is qualified in its entirety by the full text of Securities
Purchase Agreement filed as exhibit to the Prior Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d